The Src/Bcr-Abl tyrosine kinase inhibitor Saracatinib (AZD-0530) has been investigated within nasopharyngeal carcinoma as a treatment for preventing LIF-mediated increased invasiveness [81]. This evidence concerns the gene LIF and nasopharyngeal carcinoma.